Jimenez-Fonseca P., Foy V., Raby S., Carmona-Bayonas A., Macía-Rivas L., Arrazubi V., Cacho Lavin D., Hernandez San Gil R., Custodio A., Cano J.M., Fernández Montes A., Mirallas O., Macias Declara I., Vidal Tocino R., Visa L., Limón M.L., Pimentel P., Martínez Lago N., Sauri T., Martín Richard M., Mangas M., Gil Raga M., Calvo A., Reguera P., Granja M., Martín Carnicero A., Hernández Pérez C., Cerdá P., Gomez Gonzalez L., Garcia Navalon F., Pacheco Barcia V., Gutierrez Abad D., Ruiz Martín M., Weaver J., Mansoor W., Gallego J.. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359231157641. PMID:36895850. IF:4.300(Q2/3D).

Martin-Broto J., Martinez-Garcia J., Moura D.S., Redondo A., Gutierrez A., Lopez-Pousa A., Martinez-Trufero J., Sevilla I., Diaz-Beveridge R., Solis-Hernandez M.P., Carnero A., Perez M., Marcilla D., Garcia-Foncillas J., Romero P., Fernandez-Jara J., Lopez-Lopez D., Arribas I., Hindi N.. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1)DOI:10.1038/s41392-023-01661-8. PMID:37875500. IF:40.800(Q1/1D).

Hwang, TJ, Trinh, QD, Tibau, A, Vokinger, KN. Reforms to accelerated approval of new medicines: long overdue. LANCET. 2022; 400(10349)DOI:10.1016/S0140-6736(22)01276-4. PMID:35835129. IF:168.900(Q1/1D).

Lindskog, M, Laurell, A, Kjellman, A, Melichar, B, Rey, PM, Zielinski, H, Villacampa, F, Bigot, P, Zoltan, B, Parikh, O, Alba, DV, Jellvert, D, Flasko, T, Gallardo, E, Caparros, MJR, Purkalne, G, Suenaert, P, Karlsson-Parra, A, Ljungberg, B. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 2022; 40DOI:10.1016/j.euros.2022.03.012. PMID:35638086. IF:2.500(Q3/6D).

Hernandez, MH, Bote, V, Serra-LLovich, A, Cendros, M, Salazar, J, Mestres, C, Guijarro, S, Alvarez, A, Lamborena, C, Mendez, I, Sanchez, B, Hervas, A, Arranz, MJ. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders. Pharmacogenomics & Personalized Medicine. 2022; 15DOI:10.2147/PGPM.S377210. PMID:36393977. IF:1.900(Q4/9D).

Molto C., Tibau A., Bujosa A., Tapia J.C., Mittal A., Tamimi F., Amir E.. Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-25983-9. PMID:36494465. IF:(Q/D).

Isla D., Majem M.. A Paradigm Shift for Resectable Non-Small Cell Lung Cancer. ARCHIVOS DE BRONCONEUMOLOGIA. 2022; 58(12)DOI:10.1016/j.arbres.2022.04.004. PMID:35595655. IF:8.000(Q1/2D).

Argilés G., Valladares-Ayerbes M., Viéitez J.M., García-Paredes B., Rodríguez-Garrote M., Rivera F., Goldberg R.M., Ciardiello F., Tabernero J.M., Goldberg R., Argilés, Tabernero J., Mulet N., Limón M.L., Valladares M., Jiménez P., Vieitez J.M., Grávalos C., García-Alfonso P., Santos C., Páez D., Tobeña M., Sastre J., García Paredes B., Benavides M., Aranda E., Cano M.T., Loupakis F., Rguez Garrote M., Guillén C., Rivera M.F., Safont J., Hiret S., Bennouna J., Pannier D., Malka D., Falcone A., Cremolini C., The. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). EUROPEAN JOURNAL OF CANCER. 2022; 177DOI:10.1016/j.ejca.2022.09.037. PMID:36335783. IF:8.400(Q1/2D).

Martin-Broto J., Redondo A., Moura D.S., Valverde C., Morales J.M., Lopez-Pousa A., Martinez-Trufero J., Gutierrez A., Díaz-Beveridge R., Luna P., Martinez-Marin V., Marcilla D., Arribas I., Ledesma P., Lopez-Martin J.A., Di Lernia D., Zamora J., Hindi N.. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 2022; 13(1)DOI:10.1038/s41467-022-33975-6. PMID:36271011. IF:16.600(Q1/1D).

Blay J.Y., Palmerini E., Bollard J., Aguiar S., Angel M., Araya B., Badilla R., Bernabeu D., Campos F., Chs C.-S., Carvajal Montoya A., Casavilca-Zambrano S., Castro-Oliden, 5th, Chacón M., Clara-Altamirano M.A., Collini P., Correa Genoroso R., Costa F.D., Cuellar M., Dei Tos A.P., Dominguez Malagon H.R., Donati D.M., Dufresne A., Eriksson M., Farias-Loza M., Frezza A.M., Frisoni T., Garcia-Ortega D.Y., Gerderblom H., Gouin F., Gómez-Mateo M.C., Gronchi A., Haro J., Hindi N., Huanca L., Jimenez N., Karanian M., Kasper B., Lopes A., Lopes David B.B., Lopez-Pousa A., Lutter G., Maki R.G., Martinez-Said H., Martinez-Tlahuel J.L., Mello C.A., Morales Pérez J.M., Moura D.S., Nakagawa S.A., Nascimento A.G., Ortiz-Cruz E.J., Patel S., Pfluger Y., Provenzano S., Righi A., Rodriguez A., Santos T.G., Scotlandi K., Mlg S., Soulé T., Stacchiotti S., Valverde C.M., Waisberg F., Zamora Estrada E., Martin-Broto J.. Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685)). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 180DOI:10.1016/j.critrevonc.2022.103827. PMID:36220678. IF:6.200(Q1/3D).

Salvador Bofill J., Moreno Anton F., Rodriguez Sanchez C.A., Galve Calvo E., Hernando Melia C., Ciruelos Gil E.M., Vidal M., Jiménez-Rodriguez B., De la Cruz Merino L., Martínez Jañez N., Villanueva Vazquez R., de Toro Salas R., Anton Torres A., Alvarez Lopez I.M., Gavila Gregori J., Quiroga Garcia V., Vicente Rubio E., De la Haba-Rodriguez J., Gonzalez-Santiago S., Diaz Fernandez N., Barnadas Molins A., Cantos Sanchez de Ibargüen B., Delgado Mingorance J.I., Bellet Ezquerra M., de Casa S., Gimeno A., Martin M.. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. BREAST. 2022; 66DOI:10.1016/j.breast.2022.09.006. PMID:36206609. IF:3.900(Q1/3D).

Pena-Couso L., Ercibengoa M., Mercadillo F., Gómez-Sánchez D., Inglada-Pérez L., Santos M., Lanillos J., Gutiérrez-Abad D., Hernández A., Carbonell P., Letón R., Robledo M., Rodríguez-Antona C., Perea J., Urioste M., Alonso M.Á., Andrés R., Arévalo S., del Mar Arias M., Balmaña J., Beristain E., Blanco I., Boronat M., Brunet J., Cózar M.V., del Campo M., Díaz A., Gabau E., Barcina M.J., González M., Guitart M., Hernán I., Hernández H.S., Hernando S., Lacambra C., Lasa A., Lastra E., Llort G., del Rosario Marín M., Marrupe D., Martínez F., Martínez V., Martorell L., Orera M., Pedrinaci S., Pérez P., Pineda M., Plasencia A.M., Cajal T.R., Robles L., Rodà D., Rodríguez N., Rosell J., Sáez R., Salvat M., Sánchez A., Santana A., Soto J.L., Toll A., Tuneu A., Vázquez C.. Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients. Orphanet Journal of Rare Diseases. 2022; 17(1)DOI:10.1186/s13023-021-02079-7. PMID:35227301. IF:3.700(Q2/4D).

Hidalgo-Ríos S., Carrillo-García J., Moura D.S., Stacchiotti S., López-Pousa A., Redondo A., Italiano A., Gutiérrez A., Grignani G., Hindi N., López-Guerrero J.-A., Muro X.G.D., Trufero J.M., Palmerini E., García A.S., Bernabeu D., Le Cesne A., Casali P.G., Blay J.-Y., Cruz Jurado J., Martin-Broto J.. Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib. Cancers. 2022; 14(17)DOI:10.3390/cancers14174186. PMID:36077723. IF:5.200(Q2/3D).

Bellmunt J., Valderrama B.P., Puente J., Grande E., Bolós M.V., Lainez N., Vázquez S., Maroto P., Climent M.Á., Garcia del Muro X., Arranz J.Á., Durán I.. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103683. PMID:35439541. IF:6.200(Q1/3D).

Aguado-Flor E., Fuentes-Raspall M.J., Gonzalo R., Alonso C., Ramón y Cajal T., Fisas D., Seoane A., Sánchez-Pla Á., Giralt J., Díez O., Gutiérrez-Enríquez S.. Cell Senescence-Related Pathways Are Enriched in Breast Cancer Patients With Late Toxicity After Radiotherapy and Low Radiation-Induced Lymphocyte Apoptosis. Frontiers in Oncology. 2022; 12DOI:10.3389/fonc.2022.825703. PMID:35686103. IF:4.700(Q2/4D).

Provencio M., Serna-Blasco R., Nadal E., Insa A., García-Campelo M.R., Casal Rubio J., Dómine M., Majem M., Rodríguez-Abreu D., Martínez-Martí A., De Castro Carpeño J., Cobo M., López Vivanco G., Del Barco E., Bernabé Caro R., Viñolas N., Barneto Aranda I., Viteri S., Pereira E., Royuela A., Calvo V., Martín-López J., García-García F., Casarrubios M., Franco F., Sánchez-Herrero E., Massuti B., Cruz-Bermúdez A., Romero A.. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). JOURNAL OF CLINICAL ONCOLOGY. 2022; 71DOI:10.1200/JCO.21.02660. PMID:35576508. IF:45.300(Q1/1D).

Riudavets M., Auclin E., Mosteiro M., Dempsey N., Majem M., Lobefaro R., López-Castro R., Bosch-Barrera J., Pilotto S., Escalera E., Tagliamento M., Mosquera J., Zalcman G., Aboubakar-Nana F., Ponce S., Dal Maso A., Spotti M., Mielgo-Rubio X., Mussat E., Reyes R., Benítez J.-C., Lupinacci L., Duchemann B., De Giglio A., Blaquier J., Audigier-Valette C., Scheffler M., Nadal E., Lopes G., Signorelli D., Garcia-Campelo R., Menis J., Bluthgen V., Campayo M., Recondo G., Besse B., Planchard D., Mezquita L.. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. EUROPEAN JOURNAL OF CANCER. 2022; 167DOI:10.1016/j.ejca.2022.02.014. PMID:35307254. IF:8.400(Q1/2D).

Bernabé-Caro R., Garrido P., García-Campelo R., Palmero R., Artal Á., Bayona C., Rodríguez-Abreu D., López-Brea M., Paredes A., Vicente D., Torres J.M.S., Majem M., Diz P., Gordo R., Coca M., de Castro J.. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 2022; 13(1)DOI:10.18632/oncotarget.28244. PMID:. IF:(Q/D).

Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brodowicz T., Buonadonna A., De Álava E., Dei Tos A.P., Del Muro X.G., Dufresne A., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Strauss S.J., Hall K.S., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Gronchi A., Stacchiotti S., EURACAN and GENTURIS. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.005. PMID:34560242. IF:50.500(Q1/1D).

Peters S., Pujol J.-L., Dafni U., Dómine M., Popat S., Reck M., Andrade J., Becker A., Moro-Sibilot D., Curioni-Fontecedro A., Molinier O., Nackaerts K., Insa Mollá A., Gervais R., López Vivanco G., Madelaine J., Mazieres J., Faehling M., Griesinger F., Majem M., González Larriba J.L., Provencio Pulla M., Vervita K., Roschitzki-Voser H., Ruepp B., Mitchell P., Stahel R.A., Le Pechoux C., De Ruysscher D., Stahel R., Hiltbrunner A., Pardo-Contreras M., Gasca-Ruchti A., Giacomelli N., Kammler R., Marti N., Pfister R., Piguet A.C., Roux S., Troesch S., Schneider M., Schweri R., Zigomo I., Tsourti Z., Zygoura P., Tsouprou S., Kassapian M., Dimopoulou G., Andriakopoulou C., Morin F., Amour E., Mariaule G., Archirel N., Fernandez M., Pereira E., Benito L., Lopez K., Hernández A., Chinchen S., Jurkovic H., Livingstone A., Mitchell J., Walker M., Ng S., Steer C., Briscoe K., Saqib A., Abdi E., Houghton B., O'Byrne K., Chittajallu B.R., Hughes B.G., Black A., Werner H., Zalcman G., Vaylet F., Merle P., Monnet I., Girard N., Souquet P.-J., Barlesi F., Debieuvre D., Senellart H., Poudenx M., Dixmier A., Pouessel D., Cadranel J., Lena H., Quoix E., Friard S., Audigier-Valette C., Pichon E., Kokowski K., Kirchen H., Tufman A., De-Colle C., de Langen J., Insa A., Massutí B., Pulla M.P., Aix S.P., Villanueva N., Vivanco G.L., Franks K., Califano R.. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.011. PMID:34562610. IF:50.500(Q1/1D).